

Special Issue

Discovery and Validation of Novel Antimicrobial Molecules for the Treatment of Multidrug-Resistant Bacterial Infections

Message from the Guest Editors

Multidrug-resistant (MDR) bacteria represent a concerning threat to global health, thus necessitating the urgent development of innovative approaches to overcome the limited antimicrobial options against these pathogens. In this context, the validation of these novel molecules has followed rigorous microbiological, pharmacological and clinical evaluations, including in vitro and in vivo efficacy and the optimal dose of action. In this Special Issue, we intend to collect original research articles, short communications, or review articles regarding the discovery and validation of novel antimicrobial molecules against MDR pathogens. In particular, studies regarding microbiological, pharmacological and clinical studies are welcome to broaden our knowledge on these novel promising molecules.

Guest Editors

Dr. Paolo Gaibani

Department of Diagnostics and Public Health, Section of Microbiology, University of Verona, Verona, Italy

Dr. Rocco Latorre

Neurobehavioral Core, NYU Pain Research Center, Department of Molecular Pathobiology, NYU College of Dentistry, 433 1st Ave, New York, NY 10010, USA

Deadline for manuscript submissions

27 March 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/224480

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)